Edesa Biotech Inc EDSA.O:
EDESA BIOTECH REPORTS POSITIVE RESULTS IN PHASE 3 RESPIRATORY STUDY
EDESA BIOTECH INC: STUDY MET PRIMARY AND SECONDARY ENDPOINTS
EDESA BIOTECH INC - PARIDIPRUBART SHOWS 25% REDUCTION IN RISK OF DEATH
EDESA BIOTECH INC - EB05 WELL-TOLERATED IN SAFETY POPULATION OF OVER 275 SUBJECTS
EDESA BIOTECH INC - PARIDIPRUBART PLUS SOC SHOWS 13% IMPROVEMENT IN SURVIVAL
Source text: ID:nGNX1FjRDp
Further company coverage: EDSA.O